Antiviral efficacy of Unani herbal medicine in chronic hepatitis B

Evaluation for the efficacy of Qust (Saussurea lappa) and Afsanteen (Artemisia absinthium) in the management of Chronic Hepatitis B

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/11/010386

Enrollment

Registered

2017-11-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic hepatitis B Health Condition 2: B181- Chronic viral hepatitis B withoutdelta-agent

Interventions

Intervention1: 1. Qust (Saussurea lappa) 2. Afsanteen (Artemisia absinthium): 1. Decoction of crude root of qust (Saussurea lappa), 15 ml (containing approx. 1g of dried extract), advised in the morni

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically stable patients. 2. Patients of both sexes. 3. Patients in age groups of 18 to 60 years. 4. HbsAg +ve cases with a clinical history of more than 6 month. 5. Patients with HBV DNA Quantitative greater than 2,000 IU/mL. 6. ALT (alanine aminotransferase) >2 times of upper limit of normal. 7. Both HBeAg positive and negative patients.

Exclusion criteria

Exclusion criteria: 1. Children below 18 years. 2. Patient above 60 years. 3. Pregnant and lactating mothers. 4. Mentally retarded person. 5. Patients who fail to give consent. 6. Patient with cirrhosis, portal hypertension/ascites, and obstructive jaundice. 7. Patients with diabetes, and hypertension. 8. Patients with kidney and heart disease. 9. Patients with neurological disorder.

Design outcomes

Primary

Measure	Time frame
1. HBsAg loss/ negativation 2. HBeAg loss / negativation 3. In HBV DNA, Complete virologic response: a plasma HBV DNA level of less than 103 copies/mL (200 IU/mL) with normalization of ALT at week 12 (after treatment). 4. Biochemical response: Significant proportion of patients recover to normal ALT levels at 6th weeks and after 12 weeks. Timepoint: 12 weeks	—

Secondary

Measure	Time frame
1. Partial virologic response: Significant mean reduction in HBV DNA of more than 1 log10 copies/ mL 2. Significant mean change in the values of liver function tests (LFT). 3. Significant improvement in quality of life. 4. To provide tolerable and economic treatment. Timepoint: 12 weeks	—

Countries

India

Contacts

Public ContactMOHAMMAD AKHTAR SIDDIQUI

School of Unani Medicine, Jamia Hamdard

drshabnamansari.md@gmail.com9818168642

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026